hit counter
Cerecor Inc. (CERC) Stock News Sentiment & Price - Sentifly
CERC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cerecor Inc. (CERC)

USA
Biotechnology
NASDAQ
CERC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CERC Latest news
GlobeNewsWire
Neutral
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
2021-08-26 07:30

WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that it has launched its new corporate name Avalo Therapeutics, Inc. This new name reflects the Company's dedication to helping address the significant unmet medical need for patients, as well as to align with the forward momentum of its large and promising pipeline of potential first-in-class therapeutic candidates. In conjunction with the corporate name change, the Company will trade on the Nasdaq Capital Market under the new ticker symbol "AVTX". The new ticker will become effective at the open of the market on August 26, 2021. In addition, the Company will launch a new website address: www.avalotherapeutics.com.

GlobeNewsWire
Neutral
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
2021-08-02 16:01

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced recent business progress and second quarter 2021 financial results.

GlobeNewsWire
Neutral
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
2021-08-02 07:30

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn's Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments

Benzinga
Positive
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients
2021-07-27 06:16

Cerecor Inc (NASDAQ: CERC) announced initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease (CD). CERC-002 is an investigational fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (TNFSF14)) monoclonal antibody.

GlobeNewsWire
Neutral
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
2021-07-26 16:01

ROCKVILLE, Md. and CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (TNFSF14)) monoclonal antibody, in adult patients with moderate to severe Crohn's disease (CD). Crohn's disease is a disorder affecting as many as 780,000 people in the United States.

GlobeNewsWire
Neutral
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
2021-06-23 07:30

Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders

InvestorPlace
Positive
7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage
2021-05-19 05:01

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared first on InvestorPlace.

GlobeNewsWire
Neutral
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
2021-05-13 07:00

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and first quarter 2021 financial results.

PennyStocks
Positive
Top Penny Stocks to Buy Moving in Premarket? Check These 3 Out
2021-05-11 09:27

These 3 penny stocks made big moves in pre-market trading; are they worth it? The post Top Penny Stocks to Buy Moving in Premarket?

Benzinga
Positive
Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients
2021-05-11 09:15

The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14).

Loading more news...